Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Piramal Pharma Limited ( (IN:PPLPHARMA) ).
Piramal Pharma Limited’s board has approved the audited standalone and consolidated financial statements for the quarter and full year ended 31 March 2026, in line with SEBI listing regulations, and will publish the results in newspapers as required. The company also reaffirmed the integrity of these results through an unmodified statutory auditors’ report.
The board moved to strengthen management continuity and governance by re-appointing Chairperson Nandini Piramal and Executive Director Peter DeYoung as whole-time directors for three-year terms, subject to shareholder approval. In addition, independent directors Sridhar Gorthi and Peter Stevenson were re-appointed for second five-year terms from March 2027, with Stevenson’s tenure to continue beyond age 75, reinforcing board stability and regulatory compliance.
More about Piramal Pharma Limited
Piramal Pharma Limited is an India-based pharmaceutical company engaged in the development, manufacturing, and distribution of pharmaceutical products and services. Listed on BSE and NSE, it operates through multiple business segments in the pharma value chain, serving both domestic and international markets from its base in Mumbai.
Average Trading Volume: 217,020
Technical Sentiment Signal: Hold
Current Market Cap: 219.9B INR
For a thorough assessment of PPLPHARMA stock, go to TipRanks’ Stock Analysis page.